This application is written In response to RFA-HD-13-016 to participate as a Clinical Site In an ongoing multicenter cooperative program designed to conduct clinical studies Investigating problems In reproductive medicine. The application directly addresses the mission of the Reproductive Sciences Branch to ensure the birth of healthy, wanted babies through studies on human fertility and Infertility. The long term objectives of the proposed project are to Improve live birth rates in Infertile women with polycystic ovary syndrome (PCOS), and to explore the role of chronic Inflammation In the pathophysiology of PCOS-related infertility and In the response to fertility therapy in such individuals. First line therapy with clomiphene citrate falls to result In successful pregnancy In up to one-half of PCOS patients. However, the addition of dexamethasone (DEX) to CC shows promise as a safe, effective. Inexpensive intervention in this population. We thus propose the following specific alms:
Specific Aim 1. To compare the live birth rate in women with PCOS treated with CC plus placebo to that in PCOS women treated with CC plus DEX;
Specific Aim 2. To compare serum hormone levels and markers of Inflammation in women with PCOS treated with CC and placebo to those In PCOS women treated with CC plus DEX;
Specific Aim 3. To explore possible relationships between serum hormone levels and markers of Inflammation or treatment-related changes In these parameters and ovulation and live born delivery rates. We will address these specific alms by conducting a double-blind, randomized trial of ovulation Induction with CC plus DEX compared to CC plus placebo. Based on considerations described in the proposal we hypothesize that: 1) The live birth rate In women with PCOS treated with CC plus DEX will be 10% higher than the rate In women treated with CC plus placebo;2) Serum levels of dehydroeplandrosterone sulfate (DHEAS) and markers of Inflammation will be reduced significantly in subjects treated with CC plus DEX compared to women treated with CC plus placebo;3)Lower levels of markers of Inflammation In women treated with DEX will be associated with a higher likelihood of live born dellverv.
This proposal addresses an unmet need Infertile women. Up to one-half of women with PCOS either do not ovulate or do not conceive from first line therapy with clomiphene citrate (CC). Orally acting alternatives to CC have been ineffective at Increasing live born delivery rates. The alternatives of ovulation Induction with gonadotropins or In vitro fertilization place significant financial burdens and health risks on patients with PCOS due tn their risk nf ovarian hvnerstimulatinn svndrnme and multinle nreanancies.
|Mumford, Sunni L; Legro, Richard S; Diamond, Michael P et al. (2016) Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 101:3288-96|
|Hansen, Karl R; He, Amy Linnea W; Styer, Aaron K et al. (2016) Predictors of pregnancy and live-birth in couples with unexplained infertility after ovarian stimulation-intrauterine insemination. Fertil Steril 105:1575-1583.e2|
|Brower, Meredith A; Jones, Michelle R; Rotter, Jerome I et al. (2015) Further investigation in europeans of susceptibility variants for polycystic ovary syndrome discovered in genome-wide association studies of Chinese individuals. J Clin Endocrinol Metab 100:E182-6|
|Kuang, Hongying; Jin, Susan; Thomas, Tracey et al. (2015) Predictors of participant retention in infertility treatment trials. Fertil Steril 104:1236-43.e1-2|
|Diamond, Michael P; Legro, Richard S; Coutifaris, Christos et al. (2015) Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. N Engl J Med 373:1230-40|
|Hayes, M Geoffrey; Urbanek, Margrit; Ehrmann, David A et al. (2015) Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun 6:7502|
|Steiner, Anne Z; Diamond, Michael P; Legro, Richard S et al. (2015) Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. Fertil Steril 104:1522-6|
|Kuang, Hongying; Jin, Susan; Hansen, Karl R et al. (2015) Identification and replication of prediction models for ovulation, pregnancy and live birth in infertile women with polycystic ovary syndrome. Hum Reprod 30:2222-33|
|Diamond, Michael P; Legro, Richard S; Coutifaris, Christos et al. (2015) Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics. Fertil Steril 103:962-973.e4|
|Legro, Richard S; Brzyski, Robert G; Diamond, Michael P et al. (2014) The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial. Fertil Steril 101:258-269.e8|
Showing the most recent 10 out of 20 publications